CN1068893A - 新型的非甲非乙型肝炎病毒抗原多肽及诊断方法 - Google Patents
新型的非甲非乙型肝炎病毒抗原多肽及诊断方法 Download PDFInfo
- Publication number
- CN1068893A CN1068893A CN92103088A CN92103088A CN1068893A CN 1068893 A CN1068893 A CN 1068893A CN 92103088 A CN92103088 A CN 92103088A CN 92103088 A CN92103088 A CN 92103088A CN 1068893 A CN1068893 A CN 1068893A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- antigen polypeptide
- virus
- gly
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091007433 antigens Proteins 0.000 title claims abstract description 115
- 102000036639 antigens Human genes 0.000 title claims abstract description 111
- 239000000427 antigen Substances 0.000 title claims abstract description 110
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 77
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 71
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 71
- 241000700605 Viruses Species 0.000 title claims abstract description 59
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 25
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 15
- 238000002405 diagnostic procedure Methods 0.000 title description 4
- 206010019786 Hepatitis non-A non-B Diseases 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 51
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 27
- 239000002157 polynucleotide Substances 0.000 claims abstract description 27
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 27
- 238000001514 detection method Methods 0.000 claims abstract description 10
- 239000000523 sample Substances 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 7
- 238000002965 ELISA Methods 0.000 claims description 6
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 238000003757 reverse transcription PCR Methods 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102220369445 c.668T>C Human genes 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102220023257 rs387907546 Human genes 0.000 claims 2
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 claims 1
- FYRVDDJMNISIKJ-UWVGGRQHSA-N Asn-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FYRVDDJMNISIKJ-UWVGGRQHSA-N 0.000 claims 1
- TWVKGYNQQAUNRN-ACZMJKKPSA-N Ile-Ser Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O TWVKGYNQQAUNRN-ACZMJKKPSA-N 0.000 claims 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 1
- JPNRPAJITHRXRH-BQBZGAKWSA-N Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O JPNRPAJITHRXRH-BQBZGAKWSA-N 0.000 claims 1
- WEQJQNWXCSUVMA-RYUDHWBXSA-N Phe-Pro Chemical compound C([C@H]([NH3+])C(=O)N1[C@@H](CCC1)C([O-])=O)C1=CC=CC=C1 WEQJQNWXCSUVMA-RYUDHWBXSA-N 0.000 claims 1
- RZEQTVHJZCIUBT-WDSKDSINSA-N Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-WDSKDSINSA-N 0.000 claims 1
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 claims 1
- LZLREEUGSYITMX-JQWIXIFHSA-N Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)N)C(O)=O)=CNC2=C1 LZLREEUGSYITMX-JQWIXIFHSA-N 0.000 claims 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 claims 1
- 108010068380 arginylarginine Proteins 0.000 claims 1
- 102220369447 c.1352G>A Human genes 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000007689 inspection Methods 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 description 28
- 239000002299 complementary DNA Substances 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 206010008909 Chronic Hepatitis Diseases 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000013049 sediment Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 230000036770 blood supply Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000037262 Hepatitis delta Diseases 0.000 description 2
- 241000724709 Hepatitis delta virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 244000184734 Pyrus japonica Species 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- -1 beta galactose glycosides Chemical class 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- ZVUUCUFDAHKLKT-UHFFFAOYSA-M sodium;2,4,6-trinitrophenolate Chemical compound [Na+].[O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O ZVUUCUFDAHKLKT-UHFFFAOYSA-M 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 101000829954 Pan troglodytes Exonuclease GOR Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000531807 Psophiidae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 101100068489 Vicia faba AGPC gene Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP125171/91 | 1991-04-26 | ||
| JP12517191 | 1991-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1068893A true CN1068893A (zh) | 1993-02-10 |
Family
ID=14903648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN92103088A Pending CN1068893A (zh) | 1991-04-26 | 1992-04-25 | 新型的非甲非乙型肝炎病毒抗原多肽及诊断方法 |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR920019816A (enrdf_load_stackoverflow) |
| CN (1) | CN1068893A (enrdf_load_stackoverflow) |
| TW (1) | TW227566B (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106248812A (zh) * | 2016-06-28 | 2016-12-21 | 林海燕 | 一种乙肝病毒核心抗原含量检测方法 |
-
1992
- 1992-04-24 KR KR1019920006922A patent/KR920019816A/ko not_active Ceased
- 1992-04-25 CN CN92103088A patent/CN1068893A/zh active Pending
- 1992-04-25 TW TW081103269A patent/TW227566B/zh active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106248812A (zh) * | 2016-06-28 | 2016-12-21 | 林海燕 | 一种乙肝病毒核心抗原含量检测方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR920019816A (ko) | 1992-11-20 |
| TW227566B (enrdf_load_stackoverflow) | 1994-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI106564B (fi) | Menetelmä HCV-polypeptidien valmistamiseksi ja menetelmässä käytettäviä rekombinanttivektoreita | |
| CA2005950C (en) | Non-a, non-b hepatitis virus genome rna, cdna and virus antigen protein | |
| RU2155228C2 (ru) | Hcv геномные последовательности для диагностических и терапевтических целей | |
| US5428145A (en) | Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems | |
| US5427909A (en) | Oligonucleotides and determination system of HCV genotypes | |
| KR970703425A (ko) | G형 간염 바이러스 및 이것의 분자 클로닝 방법(hepatitis g virus and mo-lecular cloning thereof) | |
| He et al. | Mutations in the ‘a’determinant of hepatitis B surface antigen among Chinese infants receiving active postexposure hepatitis B immunization | |
| PL191312B1 (pl) | Wyizolowany szczep wirusa zapalenia wątroby typu B, wyizolowany kwas nukleinowy, wektor, układ gospodarz-wektor, sposób wytwarzania polipeptydu, oczyszczony polipeptyd, oligonukleotyd, sposób otrzymywania przeciwciał, przeciwciała, zastosowanie kwasu nukleinowego, zastosowanie przeciwciał, sposób oznaczania związku chemicznego, kompozycja, sposób wytwarzania kompozycji, zastosowanie kompozycji, sposób skriningu płynów ustrojowych i szczepionka | |
| CN1068893A (zh) | 新型的非甲非乙型肝炎病毒抗原多肽及诊断方法 | |
| WO1992009634A1 (en) | Non-a non-b hepatitis virus antigen protein | |
| EP0551275B1 (en) | Non-a non-b sequences | |
| CA2529997A1 (en) | Novel surface protein (hbsag) variant of hepatitis b virus | |
| JPH11510705A (ja) | 肝炎ｇｂウイルスの核酸検出 | |
| Hardie et al. | DNA single strand conformation polymorphism identifies five defined strains of hepatitis B virus (HBV) during an outbreak of HBV infection in an oncology unit | |
| WO1992001714A1 (en) | Non-a non-b hepatitis virus antigen | |
| KR0126107B1 (ko) | 비-a 비-b형 간염 바이러스 유전자에서 유래하는 dna 및 구성 폴리펩티드 | |
| JP3042864B2 (ja) | 非ａ非ｂ型肝炎ウイルス抗原ペプチド、これをコードする核酸断片およびこれらの利用法 | |
| RU2162894C2 (ru) | Полипептид, обладающий антигенными свойствами вируса гепатита с и его фрагмент (варианты), диагностический реагент (варианты), набор для обнаружения антител (варианты), способ обнаружения антител (варианты) | |
| JPH04121193A (ja) | 非ａ非ｂ型肝炎ウイルス融合ペプチドおよびその製法 | |
| EP0516270A2 (en) | Non-A, non-B hepatitis virus related antigen, antibody, detection systems, polynucleotides and polypeptides | |
| JP3148994B2 (ja) | 非ａ非ｂ型肝炎関連核酸、抗原、抗体およびこれらの検出方法 | |
| Obeid et al. | Analysis of hepatitis C virus infection among sickle cell anemia patients by an antigen-antibody combination assay | |
| JPH04169192A (ja) | 非ａ非ｂ型肝炎ウイルス抗原ポリペプチド、該抗原ポリペプチドをコードするポリヌクレオチド、及びそれらを用いた非ａ非ｂ型肝炎の診断方法 ３ | |
| JPH0568563A (ja) | Ｃ型肝炎ウイルス遺伝子およびその利用方法 | |
| WO2000063444A2 (en) | Method for detecting hepatitis c virus with hybridomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |